This study aims to assess the effects of a single dose of Zynamite® on performance across a number of cognitive domains (attention, working memory, episodic memory, executive function), as well as during a period of cognitively demanding task performance, and during laboratory-induced stress. Seventy-two healthy healthy males (50%) and females (50%) aged 18-45 years will be recruited from the general population. Participants will be randomised to receive either Zynamite® or placebo at testing visit 1, then the treatment they have not already received at testing visit 2. A single acute dose will be administered on each of the two testing visits, with at least a seven day washout period in between. The study is quantitative; participants will complete questionnaires assessing mood, cognitive tasks and an Observed Multitasking Stressor (OMS) task (with saliva samples, and blood samples for 50% of the sample). The cognitive/mood assessments will take place at baseline, then at 30, 180 and 300 minutes post-dose. The OMS assessments will take place at baseline then between 90 and 130 minutes post-dose. For participants in the bloods sub-sample, blood samples will be taken at baseline and after the 300 minute post-dose assessment. Both testing visits will be identical apart from the treatment allocated.
Age range
18 Years – 45 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Mood measures- Profile of Mood States (POMS)
Timeframe: Prior to (baseline) and following one dose of treatment (at 30, 180 and 300 minutes post dose)
Mood measures- Stress Visual Analogue Scales (VAS)
Timeframe: Following one dose of treatment at 30, 180 and 300 minutes post-dose
Mood measures- State Trait Anxiety Inventory (STAI)
Timeframe: Following one dose of treatment at 90-130 minutes post-dose
Cognitive Function- Individual task
Timeframe: Following one dose of treatment at 30, 180 and 300 min post-dose
Cognitive Function- Composite cognitive factors
Timeframe: Following one dose of treatment at 30, 180 and 300 min post-dose
Cognitive Function- cognitively demanding tasks
Timeframe: Following one dose of treatment at 30, 180 and 300 min post-dose
Cognitive Function under stressful conditions
Timeframe: Following one dose of treatment at 90-130 mins post-dose
Psychological stress response
Timeframe: Following one dose of treatment at 90-130 mins post-dose
Physiological stress response- Galvanic Skin Response
Timeframe: Following one dose of treatment at 90-130 mins post-dose
Physiological stress response- Heart Rate
Timeframe: Following one dose of treatment at 90-130 mins post-dose
Physiological stress response- BDNF Blood Markers
Timeframe: Following one dose of treatment
Physiological stress response- Adrenaline Blood Markers
Timeframe: Following one dose of treatment
Physiological stress response- Noradrenaline Blood Markers
Timeframe: Following one dose of treatment
Physiological stress response- Serum Prolactin Blood Markers
Timeframe: Following one dose of treatment
Physiological stress response- α-amylase Salivary Response
Timeframe: Following one dose of treatment at 90-130 mins post-dose
Physiological stress response- Cortisol Salivary Response
Timeframe: Following one dose of treatment at 90-130 mins post-dose